Alagille Syndrome Treatment Market, By Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin Amer
Alagille Syndrome Treatment Market, By Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
Alagille syndrome is a genetic disorder that may affect many different parts of the body including the liver, heart, eyes, face, skeleton, blood vessels, and kidneys. A person with Alagille syndrome has fewer than the normal number of small bile ducts inside the liver. Bile ducts carry bile from the liver to the gallbladder for storage and then to the first part of the small intestine, also called the duodenum, for use in digestion. With fewer small bile ducts, less bile flows out of the liver. This condition is called cholestasis. As bile builds up in the liver, it may cause liver damage. Thus, the introduction of new drugs for the treatment of alagille syndrome in the market is expected to drive the growth of the global alagille syndrome treatment market over the forecast period.
Market Dynamics
The key players in the pharmaceutical industry are focusing on the development of new drugs with different approaches and platforms for the treatment of Alagille syndrome. Thus, the introduction of such advanced products in the market is expected to drive the growth of the global alagille syndrome treatment market over the forecast period. For instance, on June 13, 2023, Ipsen Pharma, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille Syndrome (ALGS).
Key features of the study:
This report provides an in-depth analysis of the global alagille syndrome treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global alagille syndrome treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Ipsen Pharma, and CANbridge Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global alagille syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alagille syndrome treatment market